Asahi Kasei regains naftopidil rights
This article was originally published in Scrip
Executive Summary
Japan's Asahi Kasei Pharma has regained the rights to certain intellectual property relating to its alpha1-antagonist naftopidil from Roche Diagnostics. The financial terms of the transaction were not disclosed. Asahi Kasei markets various formulations of the product in Japan as Flivas for the treatment of benign prostatic hyperplasia, and said it was looking to expand both domestic and overseas sales. It expects Japanese sales of the product to reach ¥9.8 billion ($100.9 million) this fiscal year and has begun Phase II trials for the additional indication of neurogenic bladder.